Development of a toxin-selective immunotracer for in vivo detection of Clostridioides difficile infection by immunoPET., PMID:40512279
Evaluation of the Potency of the First Commercial Vaccine for Clostridioides difficile Infection in Piglets and Comparison with the Humoral Response in Rabbits., PMID:40432050
Clostridium difficile as a potent trigger of colorectal carcinogenesis., PMID:40411629
Anti-interleukin-23 treatment linked to improved Clostridioides difficile infection survival., PMID:40114558
IL-33 protects from recurrent C. difficile infection by restoration of humoral immunity., PMID:40048372
Polymorphonuclear neutrophil depletion in ileal tissues reduces the immunopathology induced by Clostridioides difficile toxins., PMID:40023364
Clostridioides difficile major toxins remodel the intestinal epithelia, affecting spore adherence/internalization into intestinal tissue and their association with gut vitronectin., PMID:39974910
Cell Wall Protein 2 as a Vaccine Candidate Protects Mice Against Clostridioides difficile Infection., PMID:39852800
Clostridioides difficile binary toxin CDT induces biofilm-like persisting microcolonies., PMID:39719371
Anti-Interleukin-23 Treatment Linked to Improved Clostridioides difficile Infection Survival., PMID:39677433
IL-33 protects from recurrent C. difficile infection by restoration of humoral immunity., PMID:39605647
Safety and Immunogenicity of an Adjuvanted Clostridioides difficile Vaccine Candidate in Healthy Adults: A Randomized Placebo-Controlled Phase 1 Study., PMID:39447053
[Clostridioides difficile infections: Update and therapeutic guidelines]., PMID:39377303
Identification and preclinical evaluation of MMV676558 as a promising therapeutic candidate against Clostridioides difficile., PMID:39321508
Clostridioides difficile infection: an update., PMID:39282548
Development of two recombinant vaccines against Clostridioides difficile infection and immunogenicity in pregnant sows and neonatal piglets., PMID:39127403
Current and Ongoing Developments in Targeting Clostridioides difficile Infection and Recurrence., PMID:38930588
Understanding host immune responses in Clostridioides difficile infection: Implications for pathogenesis and immunotherapy., PMID:38898983
A sequence invariable region in TcdB2 is required for toxin escape from Clostridioides difficile., PMID:38888328
Inhibition of EGFR/ErbB does not protect against C. difficile toxin B., PMID:38798529
Clostridioides difficile toxin B subverts germinal center and antibody recall responses by stimulating a drug-treatable CXCR4-dependent mechanism., PMID:38761377
Monoclonal antibody-mediated neutralization of Clostridioides difficile toxin does not diminish induction of the protective innate immune response to infection., PMID:38701911
Advances in Therapeutic Strategies for the Management of Clostridioides difficile Infection., PMID:38592194
New treatment approaches for Clostridioides difficile infections: alternatives to antibiotics and fecal microbiota transplantation., PMID:38591915
The impact of existing total anti-toxin B IgG immunity in outcomes of recurrent Clostridioides difficile infection., PMID:38552897
Enhancing bezlotoxumab binding to C. difficile toxin B2: insights from computational simulations and mutational analyses for antibody design., PMID:38511411
Evaluation of MALDI-TOF mass spectrometry coupled with ClinProTools as a rapid tool for toxin-producing Clostridioides difficile., PMID:38423297
Anti-S-layer monoclonal antibodies impact Clostridioides difficile physiology., PMID:38289292
Multimodal vaccination targeting the receptor binding domains of Clostridioides difficile toxins A and B with an attenuated Salmonella Typhimurium vector (YS1646) protects mice from lethal challenge., PMID:38189293
An Updated View on the Cellular Uptake and Mode-of-Action of Clostridioides difficile Toxins., PMID:38175478
Immunization Strategies Against Clostridioides difficile., PMID:38175474
Engineered Secretory Immunoglobulin A provides insights on antibody-based effector mechanisms targeting Clostridiodes difficile., PMID:37986930
A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of age., PMID:37977942
Nanobodies against C. difficile TcdA and TcdB reveal unexpected neutralizing epitopes and provide a toolkit for toxin quantitation in vivo., PMID:37871122
Biofilm Formation of Clostridioides difficile, Toxin Production and Alternatives to Conventional Antibiotics in the Treatment of CDI., PMID:37764005
Exploring the inhibitory potential of the antiarrhythmic drug amiodarone against Clostridioides difficile toxins TcdA and TcdB., PMID:37749884
Co-administration of an effector antibody enhances the half-life and therapeutic potential of RNA-encoded nanobodies., PMID:37670025
Development and characterization of phage display-derived anti-toxin antibodies neutralizing TcdA and TcdB of Clostridioides difficile., PMID:37668373
A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults Aged 65 to 85 Years., PMID:37531657
Efficacy, Safety, and Cost-effectiveness of Bezlotoxumab in Preventing Recurrent Clostridioides difficile Infection : Systematic Review and Meta-analysis., PMID:37395627
[Update in diagnosis and management of Clostridioides difficile]., PMID:39093178
Establishment of a Novel Detection Platform for Clostridioides difficile Toxin Genes Based on Orthogonal CRISPR., PMID:37378559
Elucidation of bezlotoxumab binding specificity to toxin B in Clostridioides difficile., PMID:37098802
Structural Basis for Binding of Neutralizing Antibodies to Clostridioides difficile Binary Toxin., PMID:36951574
Recombinant Fusion Protein Vaccine Containing Clostridioides difficile FliC and FliD Protects Mice against C. difficile Infection., PMID:36939332
Neutralising Effects of Different Antibodies on Clostridioides difficile Toxins TcdA and TcdB in a Translational Approach., PMID:36835278
Clostridioides difficile-mesocolonic oedema in neonatal suckling piglets develops regardless of the fibre composition in sow's diets., PMID:36621110
Comparative biofilm-forming ability between Clostridioides difficile strains isolated in Latin America and the epidemic NAP1/027 strain., PMID:36619751
Rapid-format recombinant antibody-based methods for the diagnosis of Clostridioides difficile infection: Recent advances and perspectives., PMID:36523835
Neutralizing epitopes on Clostridioides difficile toxin A revealed by the structures of two camelid VHH antibodies., PMID:36466927
For research use only. Not for human or drug use.
